NOVONIX director reports 195,938 share rights
NOVONIX Ltd director Jean Oelwang reported a derivative holding of 195,938 share rights linked to ordinary shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
NOVONIX Ltd director Jean Oelwang reported a derivative holding of 195,938 share rights linked to ordinary shares. These share rights have an exercise price of $0.0000 and are scheduled to expire on December 31, 2027. The filing shows 195,938 underlying ordinary shares associated with this position, with no buy or sell transactions indicated in the provided data.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Share rights | -- | -- | -- |
Key Figures
Key Terms
Exercise price financial
Expiration date financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider position did NOVONIX (NVX) director Jean Oelwang report?
How many NOVONIX (NVX) securities does Jean Oelwang hold after this Form 4 entry?
Is Jean Oelwang’s NOVONIX (NVX) position direct or indirect in this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.